2017
DOI: 10.1016/j.canlet.2017.05.016
|View full text |Cite
|
Sign up to set email alerts
|

BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

5
57
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
6

Relationship

2
4

Authors

Journals

citations
Cited by 64 publications
(62 citation statements)
references
References 56 publications
5
57
0
Order By: Relevance
“…Further, BZML‐treated A549 and A549/Taxol cells in the presence or absence of NAC for 72 hours were detected by Annexin V‐FITC/PI staining and the MTT assay. However, the phosphatidylserine in outer cell membrane (Annexin V‐FITC positive) is a marker of apoptosis, and BZML‐induced MC also possesses this feature in A549/Taxol cells . Here, the BZML‐induced Annexin V‐FITC‐positive cells were clearly reduced by NAC in A549 cells, but not in A549/Taxol cells (Figure C).…”
Section: Resultsmentioning
confidence: 91%
See 2 more Smart Citations
“…Further, BZML‐treated A549 and A549/Taxol cells in the presence or absence of NAC for 72 hours were detected by Annexin V‐FITC/PI staining and the MTT assay. However, the phosphatidylserine in outer cell membrane (Annexin V‐FITC positive) is a marker of apoptosis, and BZML‐induced MC also possesses this feature in A549/Taxol cells . Here, the BZML‐induced Annexin V‐FITC‐positive cells were clearly reduced by NAC in A549 cells, but not in A549/Taxol cells (Figure C).…”
Section: Resultsmentioning
confidence: 91%
“…A549 and A549/Taxol cells were grown in RPMI 1640 supplemented with 10% FBS at 37°C with 5% CO 2 in a humidified incubator. A549/Taxol cells were periodically cultured in 300 nM Taxol to maintain MDR and shifted into Taxol‐free medium for 1 week before used …”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…Currently, ABI‐231, as VERU‐111, is under clinical trials in men with advanced castration resistant prostate cancer (NCT 03752099). The compounds exhibited similar potency to MDR cells compared with corresponding parent cells . They also demonstrated synergistic action through the combination of ABI‐274 and vemurafenib to overcome vemurafenib‐acquired resistance in BRAF (V600E) melanoma.…”
Section: Mechanisms Of Multidrug Resistancementioning
confidence: 94%
“…Mechanistic studies showed that BZML decreased P‐gp expression at the protein and mRNA levels. Cell morphology changes and the expression of apoptosis‐related proteins denoted that BZML‐induced mitotic catastrophe to A549/taxol‐resistant cells in a p53‐independent, apoptotic‐like pathway, whereas BZML‐caused apoptosis to A549 cells . Verubulin (MPC‐6827) ( 30 ) is a quinazoline derivative that showed potent antineoplastic activities against diverse tumors and promoted apoptosis in both sensitive and MDR cancer cell phenotypes .…”
Section: Mechanisms Of Multidrug Resistancementioning
confidence: 99%